Efficacy and safety in sitagliptin therapy for diabetes complicated by chronic liver disease caused by hepatitis C virus

Hepatology Research

Volumn 41, Issue 6, 2011, Pages 524-529

  Arase, Yasuji ^a,b   Suzuki, Fumitaka ^a   Kobayashi, Mariko ^a   Suzuki, Yoshiyuki ^a   Kawamura, Yusuke ^a   Matsumoto, Naoki ^a   Akuta, Norio ^a   Imai, Norihisa ^a   Kobayashi, Masahiro ^a   Sezaki, Hitomi ^a   Saito, Satoshi ^a   Hosaka, Tetsuya ^a   Ikeda, Kenji ^a   Kumada, Hiromitsu ^a   Ohmoto, Yuki ^a   Amakawa, Kazuhisa ^a   Tsuji, Hiroshi ^a   Hsieh, Shium Dong ^a   Kobayashi, Tetsurou ^b  

^a TORANOMON HOSPITAL   (Japan)

^b UNIVERSITY OF YAMANASHI   (Japan)

Author keywords

Hepatitis C virus; Sitagliptin; Type 2 diabetes mellitus

Indexed keywords

DIPEPTIDYL PEPTIDASE IV INHIBITOR; HEMOGLOBIN A1C; SITAGLIPTIN;

ABSENCE OF SIDE EFFECTS; ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CASE CONTROL STUDY; CHRONIC LIVER DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; DRUG EFFICACY; DRUG SAFETY; FEMALE; FOLLOW UP; GLUCOSE BLOOD LEVEL; HEPATITIS C VIRUS; HUMAN; LIVER FUNCTION; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; RETROSPECTIVE STUDY; TREATMENT OUTCOME;

EID: 79957551356     PISSN: 13866346     EISSN: 1872034X     Source Type: Journal    
DOI: 10.1111/j.1872-034X.2011.00798.x     Document Type: Article

References (26)

1. Kiyosawa K, Furuta S. Review of hepatitis C in Japan. J Gastroenterol Hepatol 1991; 6: 383-91.
2. Alter MJ, Margolis HS, Krawczynski K etal. The natural history of community acquired hepatitis C in the United States. N Engl J Med 1992; 327: 1899-905.
3. van Rossum TG, Vulto AG, de Man RA, Brouwer JT, Schalm SW. Review article: glycyrrhizin as a potential treatment for chronic hepatitis C. Aliment Pharmacol Ther 1998; 12: 199-205.
4. Colombo M, Kuo G, Choo QL etal. Prevalence of antibodies to hepatitis C virus in Italian patients with hepatocellular carcinoma. Lancet 1989; 2: 1006-8.
5. Hasan F, Jeffers LJ, De Medina M etal. Hepatitis C-associated hepatocellular carcinoma. Hepatology 1990; 12: 589-91.
6. Kew MC, Houghton M, Choo QL, Kuo G. Hepatitis C virus antibodies in southern African blacks with hepatocellular carcinoma. Lancet 1990; 335: 873-4.
7. Tsukuma H, Hiyama T, Tanaka S etal. Risk factors for hepatocellular carcinoma among patients with chronic liver disease. N Engl J Med 1993; 328: 1797-801.
8. Ikeda K, Saitoh S, Koida I etal. A multivariate analysis of risk factors for hepatocellular carcinogenesis: a prospective observation of 795 patients with viral and alcoholic cirrhosis. Hepatology 1993; 18: 47-53.
9. Imazeki F, Yokosuka O, Fukai K, Kanda T, Kojima H, Saisho H. Prevalence of diabetes mellitus and insulin resistance in patients with chronic hepatitis C: comparison with hepatitis B virus-infected and hepatitis C virus-cleared patients. Liver Int 2008; 28: 355-62.
10. Arao M, Murase K, Kusakabe A etal. Prevalence of diabetes mellitus in Japanese patients infected chronically with hepatitis C virus. J Gastroenterol 2003; 38: 355-60.
11. Arase Y, Suzuki F, Suzuki Y etal. Sustained virological response reduces incidence of onset of type 2 diabetes in chronic hepatitis C. Hepatology 2009; 49: 739-44.
12. Simó R, Lecube A, Genescà J, Esteban JI, Hernández C. Sustained virological response correlates with reduction in the incidence of glucose abnormalities in patients with chronic hepatitis C virus infection. Diabetes Care 2006; 29: 2462-6.
13. Romero-Gómez M, Fernández-Rodríguez CM, Andrade RJ etal. Effect of sustained virological response to treatment on the incidence of abnormal glucose values in chronic hepatitis C. J Hepatol 2008; 48: 721-27.
14. Shintani Y, Fujie H, Miyoshi H etal. Hepatitis C virus infection and diabetes: direct involvement of the virus in the development of insulin resistance. Gastroenterology 2004; 126: 840-8.
15. Rouabhia S, Malek R, Bounecer H etal. Prevalence of type 2 diabetes in Algerian patients with hepatitis C virus infection. World J Gastroenterol 2010; 16: 3427-31.
16. Kawamura Y, Arase Y, Ikeda K etal. Diabetes enhances hepatocarcinogenesis in noncirrhotic, interferon-treated hepatitis C patients. Am J Med 2010; 123: 951-6, e1.
17. Kawamura Y, Ikeda K, Arase Y etal. Diabetes mellitus worsens the recurrence rate after potentially curative therapy in patients with hepatocellular carcinoma associated with nonviral hepatitis. J Gastroenterol Hepatol 2008; 23: 1739-46.
18. Veldt BJ, Chen W, Heathcote EJ etal. Increased risk of hepatocellular carcinoma among patients with hepatitis C cirrhosis and diabetes mellitus. Hepatology 2008; 47: 1856-62.
19. Imai K, Takai K, Nishigaki Y etal. Insulin resistance raises the risk for recurrence of stage 1 hepatocellular carcinoma after curative radiofrequency ablation in hepatitis C virus-positive patients. Hepatol Res 2010; 40: 376-82.
20. Nauck MA, Meininger G, Sheng D, Terranella L, Stein PP. Sitagliptin Study 024 Group. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double-blind, non-inferiority trial. Diabetes Obes Metab 2007; 9: 194-205.
21. Vincent SH, Reed JR, Bergman AJ etal. Metabolism and excretion of the dipeptidyl peptidase 4 inhibitor [14C]sitagliptin in humans. Drug Metab Dispos 2007; 35: 533-8.
22. Drucker DJ, Nauck MA. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 2006; 368: 1696-705.
23. Ikeda K, Saitoh S, Kobayashi M etal. Distinction between chronic hepatitis and liver cirrhosis in patients with hepatitis C virus infection. Practical discriminant function using common laboratory data. Hepatol Res 2000; 18: 252-66.
24. Genuth S, Alberti KG, Bennett P etal. Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Follow-up report on the diagnosis of diabetes mellitus. Diabetes Care 2003; 26: 3160-7.
25. The Committee of Japan Diabetes Society on the Diagnostic Criteria of Diabetes Mellitus. Report of the Committee on the classification and diagnostic criteria of diabetes mellitus. J Jpn Diabetes Soc 2010; 53: 450-67.
26. Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 2004; 27: 1047-53.